HiCM 288
Alternative Names: HiCM-288Latest Information Update: 31 Mar 2023
At a glance
- Originator Help Therapeutics
- Class Cardiovascular therapies; Cell therapies; Gene therapies; Induced pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cardiovascular disorders
Most Recent Events
- 30 Mar 2023 Preclinical trials in Cardiovascular disorders in China (Parenteral), prior to March 2023 (Help Therapeutics pipeline, March 2023)